文献速递关节外科

代谢综合征与髋膝关节置换术后两年患者报告结局

Metabolic syndrome and patient-reported outcome two years after hip and knee arthroplasty.
PubMed 文献 · Bone Joint J · 2024-10-01

在丹麦一项纳入2586例择期单侧髋膝关节置换患者的前瞻性队列中,62.3%符合代谢综合征标准,代谢综合征组与非代谢综合征组在基线至术后12个月的牛津髋/膝评分改善程度相似,且至24个月各时间点EQ-5D-5L、EQ-VAS、UCLA活动量表和遗忘关节评分均相似。

要点

  • 代谢综合征组与非代谢综合征组术后12个月牛津髋/膝评分改善程度无显著差异。
  • 术后3、12、24个月EQ-5D-5L、EQ-VAS、UCLA活动量表和遗忘关节评分组间均相似。
  • 代谢综合征患者髋膝关节置换术后患者报告结局改善与非代谢综合征患者相同。

核心结论

  • 符合代谢综合征标准的患者在髋膝关节置换术后24个月内获得与非代谢综合征个体相同的患者报告结局评分改善。
  • 作者认为临床医生在评估和建议代谢综合征患者时应考虑这一信息。

研究设计与样本

  • 前瞻性队列研究,2017年5月1日至2019年11月30日在丹麦建立,纳入2586例择期单侧髋膝关节置换患者。
  • 使用国家登记数据库和本地数据库判定代谢综合征,收集基线及术后3、12、24个月牛津髋/膝评分、EQ-5D-5L、UCLA活动量表和遗忘关节评分。
  • 采用广义线性混合模型校正年龄、性别、Charlson合并症指数和吸烟,计算边际均值和95%CI。

主要发现

  • 62.3%(1611/2586)的患者符合代谢综合征标准。
  • 术后12个月牛津髋评分平均改善:代谢综合征组22.5(95%CI 21.8至23.1)vs 非代谢综合征组22.1(95%CI 21.3至22.8),p=0.477。
  • 术后12个月牛津膝评分平均改善:代谢综合征组18.0(95%CI 17.4至18.6)vs 非代谢综合征组17.8(95%CI 17.0至18.7),p=0.722。
  • 术后3、24个月牛津髋/膝评分以及各时间点EQ-5D-5L、EQ-VAS、UCLA活动量表和遗忘关节评分的组间改善均相似。

关键数值与推荐

  • 主要结局为基线至术后12个月牛津髋/膝评分组间差异。
  • 次要结局为术后3、24个月牛津髋/膝评分及术后3、12、24个月EQ-5D-5L、UCLA活动量表和遗忘关节评分。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为临床医生在评估和建议代谢综合征患者时应考虑该研究结论。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The influence of metabolic syndrome (MetS) on the outcome after hip and knee arthroplasty is debated. We aimed to investigate the change in patient-reported outcome measure (PROM) scores after hip and knee arthroplasty, comparing patients with and without MetS. METHODS: From 1 May 2017 to 30 November 2019, a prospective cohort of 2,586 patients undergoing elective unilateral hip and knee arthroplasty was established in Denmark. Data from national registries and a local database were used to determine the presence of MetS. Patients' scores on Oxford Hip Score (OHS) or Oxford Knee Score (OKS), EuroQol five-dimension five-level questionnaire (EQ-5D-5L), University of California, Los Angeles (UCLA) Activity Scale, and Forgotten Joint Score (FJS) at baseline, three, 12, and 24 months after surgery were collected. Primary outcome was the difference between groups from baseline to 12 months in OHS and OKS. Secondary outcomes were scores of OHS and OKS at three and 24 months and EQ-5D-5L, UCLA Activity Scale, and FJS at three, 12, and 24 months after surgery. Generalized linear mixed model was applied, adjusting for age, sex, Charlson Comorbidity Index, and smoking to present marginal mean and associated 95% CIs. RESULTS: A total of 62.3% (1,611/2,586) of the cohort met the criteria for MetS. Both groups showed similar increase in mean OHS (MetS group 22.5 (95% CI 21.8 to 23.1), non-MetS group 22.1 (21.3 to 22.8); p = 0.477) and mean OKS (MetS group 18.0 (17.4 to 18.6), non-MetS group 17.8 (17.0 to 18.7); p = 0.722) at 12 months' follow-up. Between groups, similar improvements were seen for OHS and OKS at three and 24 months postoperatively and for the mean EQ-5D-5L, EuroQol-visual analogue scale (EQ-VAS), UCLA Activity Scale, and FJS at every timepoint. CONCLUSION: Patients meeting the criteria for MetS obtain the same improvement in PROM scores as individuals without MetS up to 24 months after hip and knee arthroplasty. This is important for the clinician to take into account when assessing and advising patients with MetS.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Sørensen RR, Timm S, Rasmussen LE, et al. Metabolic syndrome and patient-reported outcome two years after hip and knee arthroplasty. Bone Joint J. 2024. PMID: 39348914. doi:10.1302/0301-620X.106B10.BJJ-2024-0087.R1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。